April 18, 2011
NovoTTF-100A System Approved for Recurrent Glioblastoma Multiforme Brain Tumors
NovoTTF-100A treated patients reported better quality of life scores and fewer side effects during the trial compared with patients treated with chemotherapy. Specifically, quality of life using the device was better than that of chemotherapy patients in the following subscale domains: vomiting, nausea, pain, diarrhea, constipation, cognitive functioning and emotional functioning.
The NovoTTF-100A is a portable, non-invasive, wearable device which weighs about six pounds (three kilograms). It exerts its anti-cancer effects by creating a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.
For more information visit www.novocure.com.